Navigation Links
EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting
Date:5/15/2009

program for ENMD-2076 is expanding with the addition of the myeloma clinical study announced earlier and with this new study in patients with leukemia. Also, plans are underway to expand the solid tumor study at the maximum tolerated dose of ENMD-2076 to further define the objectives of safety, pharmacokinetics and antitumor activity. We believe the current clinical program allows us to quickly add new patients to establish the potential of ENMD-2076 and provide a focus for Phase 2 development. These data serve as a foundation to continue discussions with potential development partners for ENMD-2076."

About ENMD-2076

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. Preclinical studies with ENMD-2076 demonstrate significant antitumor activity, including tumor regression, in multiple solid and hematological malignancies. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to Aurora A kinase and other oncogenic proteins. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 targets a defined set of kinases, including Flt-3 and FGFR3, which have been shown to play important roles in the pathology of hematological cancers.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing primarily ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in Phase 1 studies in advanced cancers and multiple myeloma. The Company's other therapeutic candidates include MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway currently in multiple Phase 2 clinical trials for cancer, and ENMD-1198, a novel antimitotic agent currently in Phase 1 studies in advanced cancers. The Company a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma
2. EntreMed to Present at the New York Society of Security Analysts Industry Conference
3. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
4. EntreMed Reports Third Quarter 2008 Financial Results
5. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
6. EntreMed to Present at BioPartnering Europe Conference
7. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
8. EntreMed Reports Second Quarter 2008 Financial Results
9. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
10. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
11. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Rhythm, a biopharmaceutical ... genetic deficiencies that result in metabolic disorders, announced today ... S-1 with the U.S. Securities and Exchange Commission (SEC) ... of its common stock. The number of shares to ... have not yet been determined. Citigroup and ...
(Date:8/27/2014)... nature,s mysteries is how plants survive impact by ... sun,s rays, while using this energy for photosynthesis. ... the plant,s blades quickly dissipate the energy throughout ... Researchers at DTU Physics have now managed to ... and bacteria contain light-absorbing proteins which play a ...
(Date:8/27/2014)... ANGELES , Aug. 27, 2014  Lisa Kulik ... years this July 4 holiday, thanks to a groundbreaking ... Ph.D., an internationally renowned clinician-researcher at the University of ... a 55-year-old Peoria, Ariz. resident ... robs its victims of sight. On June 2, she ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
Breaking Biology Technology:Rhythm Files Registration Statement for Proposed Initial Public Offering 2DTU researchers film protein quake for the first time 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4
... QIAGEN (Nasdaq: QGEN , Frankfurt: QIA), which ... States offices in five locations, brought on board its ... as a symbol of the biotech company,s continued strong ... both in the U.S. and abroad. QIAGEN is the ...
... Phase 3 Combination Rule Trial for NDA Submission , ... BEDMINSTER, N.J., Dec. 15 QRxPharma Limited (ASX: QRX ... on the development and commercialization of therapies for pain ... of a comparative study to evaluate the efficacy and ...
... Inc. (Amex: ANX ), a biopharmaceutical company ... primarily for the treatment of cancer, today announced that ... the sale or disposition of one or more of ... other transactions that maximize the value of Company,s assets. ...
Cached Biology Technology:QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 2QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 3QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations 4QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy 2QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy 3ADVENTRX Exploring Strategic Options 2ADVENTRX Exploring Strategic Options 3ADVENTRX Exploring Strategic Options 4
(Date:8/27/2014)... A growing number of consumers are willing to pay ... "organic", but whether they,re getting what the label claims ... tomatoes are devising a new way to make sure ... appears in ACS, Journal of Agricultural and Food ... Researchers from the Bavarian Health and Food Safety Authority ...
(Date:8/27/2014)... lost or abandoned each year in U.S. waters and ... to catch fish, crabs, and other species such as ... and the watermen who depend on the resources--losses that ... study. , The report, published in the Marine ... to examine the derelict fish trap problem, and so-called ...
(Date:8/27/2014)... main factors thought to be associated with outcomes ... the age of the patient, mechanism of injury, ... repair method, operation technique, and repair materials. However, ... of peripheral nerve injuries, there is no agreement ... and the dose-effect relationship of the predictors has ...
Breaking Biology News(10 mins):NOAA's Marine Debris Program reports on the national issue of derelict fishing traps 2
... Researchers using an extremely fast and accurate imaging technique have ... shuttle material within living cells. The motors cooperate in a ... tug of war many scientists had imagined. , "We ... do not compete for control, even though they want to ...
... Yale, in collaboration with NIH researchers, have identified a ... system for detection of parasitic infections, leading the way ... , Published in the April 28 issue of Science ... parasites interface with the immune system--a problem of great ...
... from the first clinical trial of a therapeutic cancer ... (ProMuneTM, Coley Pharmaceutical), with a peptide antigen were reported ... shows that the CpG 7909 DNA sequence is safe, ... destroy cancer cells. The Phase I study was conducted ...
Cached Biology News:Molecular Motors Cooperate In Moving Cellular Cargo, Study Shows 2Yale researchers identify molecule for detecting parasitic infection in humans 2Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy 2
... Second Mitochondria Derived Activator of ... 20 mM HEPES, pH 7.5 AVOID FREEZE/THAW CYCLES. ... Smac/DIABLO with a carboxy terminal His•Tag ® ... E. coli . Smac/DIABLO is released along with ...
...
... Fixed clamp trays and universal ... Magnetic drive Shaking ... 25 mm amplitude ... to 2000 ml, including Fernbach flasks ...
... the NEW VSOS-4P, all Programmable and Digital Orbital ... now been redesigned to make every day use ... Programmable memory for up to 4 different programs. ... of your program. Furthermore, the VSOS-4P has a ...
Biology Products: